D
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Price:
19.07
CNY
-0.68%
Market Closed
Market Cap:
¥21.7B
Balance Sheet
Balance Sheet Decomposition
DaShenLin Pharmaceutical Group Co Ltd
DaShenLin Pharmaceutical Group Co Ltd
Balance Sheet Decomposition is not available for
DaShenLin Pharmaceutical Group Co Ltd
DaShenLin Pharmaceutical Group Co Ltd
Balance Sheet
DaShenLin Pharmaceutical Group Co Ltd
DaShenLin Pharmaceutical Group Co Ltd
Currency: CNY
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
603
|
527
|
668
|
1 081
|
712
|
1 180
|
3 271
|
2 247
|
3 776
|
2 997
|
3 233
|
|
| Cash |
0
|
1
|
0
|
0
|
0
|
1
|
0
|
2 247
|
3 776
|
2 997
|
3 233
|
|
| Cash Equivalents |
603
|
526
|
668
|
1 081
|
712
|
1 179
|
3 271
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
680
|
100
|
904
|
890
|
109
|
92
|
42
|
22
|
|
| Total Receivables |
229
|
212
|
333
|
428
|
481
|
576
|
700
|
1 110
|
1 514
|
1 867
|
1 978
|
|
| Accounts Receivables |
105
|
111
|
207
|
247
|
277
|
356
|
432
|
739
|
1 017
|
1 216
|
1 289
|
|
| Other Receivables |
124
|
101
|
126
|
181
|
204
|
220
|
268
|
370
|
496
|
651
|
689
|
|
| Inventory |
756
|
1 010
|
1 305
|
1 717
|
1 886
|
2 055
|
2 683
|
3 630
|
3 872
|
4 181
|
4 128
|
|
| Other Current Assets |
100
|
67
|
97
|
149
|
847
|
754
|
752
|
772
|
1 415
|
1 711
|
3 226
|
|
| Total Current Assets |
1 688
|
1 816
|
2 404
|
4 055
|
4 025
|
5 468
|
8 297
|
7 868
|
10 670
|
10 798
|
12 586
|
|
| PP&E Net |
442
|
564
|
664
|
1 011
|
1 041
|
1 166
|
1 375
|
5 727
|
6 145
|
7 343
|
7 317
|
|
| PP&E Gross |
0
|
564
|
664
|
1 011
|
1 041
|
1 166
|
1 375
|
5 727
|
6 145
|
7 343
|
7 317
|
|
| Accumulated Depreciation |
0
|
125
|
165
|
226
|
323
|
447
|
597
|
3 199
|
3 709
|
4 261
|
4 797
|
|
| Intangible Assets |
50
|
64
|
67
|
114
|
288
|
385
|
539
|
676
|
701
|
1 880
|
1 991
|
|
| Goodwill |
14
|
14
|
126
|
162
|
534
|
984
|
1 334
|
2 060
|
2 364
|
3 024
|
3 522
|
|
| Long-Term Investments |
0
|
8
|
58
|
109
|
180
|
155
|
185
|
235
|
177
|
215
|
166
|
|
| Other Long-Term Assets |
171
|
194
|
261
|
372
|
469
|
514
|
602
|
770
|
786
|
864
|
858
|
|
| Other Assets |
14
|
14
|
126
|
162
|
534
|
984
|
1 334
|
2 060
|
2 364
|
3 024
|
3 522
|
|
| Total Assets |
2 365
N/A
|
2 658
+12%
|
3 580
+35%
|
5 823
+63%
|
6 537
+12%
|
8 672
+33%
|
12 332
+42%
|
17 336
+41%
|
20 841
+20%
|
24 123
+16%
|
26 440
+10%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
509
|
586
|
752
|
901
|
884
|
1 312
|
1 651
|
2 053
|
6 127
|
6 871
|
8 433
|
|
| Accrued Liabilities |
128
|
132
|
179
|
211
|
262
|
339
|
448
|
500
|
827
|
765
|
693
|
|
| Short-Term Debt |
970
|
750
|
1 099
|
1 702
|
2 018
|
2 031
|
2 823
|
2 946
|
802
|
952
|
2 072
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
29
|
29
|
5
|
5
|
1
|
906
|
982
|
1 056
|
1 220
|
|
| Other Current Liabilities |
72
|
73
|
135
|
154
|
245
|
315
|
545
|
771
|
969
|
1 811
|
1 289
|
|
| Total Current Liabilities |
1 679
|
1 541
|
2 194
|
2 997
|
3 414
|
4 003
|
5 468
|
7 176
|
9 708
|
11 454
|
13 707
|
|
| Long-Term Debt |
96
|
81
|
29
|
0
|
21
|
260
|
1 207
|
4 204
|
4 252
|
4 713
|
4 576
|
|
| Minority Interest |
75
|
0
|
25
|
50
|
49
|
92
|
188
|
457
|
652
|
1 109
|
1 241
|
|
| Other Liabilities |
15
|
15
|
15
|
23
|
15
|
77
|
83
|
20
|
18
|
23
|
19
|
|
| Total Liabilities |
1 865
N/A
|
1 637
-12%
|
2 263
+38%
|
3 070
+36%
|
3 499
+14%
|
4 432
+27%
|
6 947
+57%
|
11 857
+71%
|
14 629
+23%
|
17 299
+18%
|
19 543
+13%
|
|
| Equity | ||||||||||||
| Common Stock |
200
|
360
|
360
|
400
|
400
|
540
|
659
|
791
|
949
|
1 139
|
1 139
|
|
| Retained Earnings |
229
|
624
|
910
|
1 385
|
1 677
|
2 140
|
2 874
|
2 933
|
3 573
|
4 170
|
4 381
|
|
| Additional Paid In Capital |
71
|
37
|
47
|
967
|
961
|
1 515
|
1 762
|
1 643
|
1 537
|
1 355
|
1 288
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
99
|
78
|
37
|
30
|
101
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
46
|
190
|
190
|
190
|
190
|
190
|
|
| Total Equity |
500
N/A
|
1 021
+104%
|
1 317
+29%
|
2 753
+109%
|
3 038
+10%
|
4 240
+40%
|
5 385
+27%
|
5 479
+2%
|
6 212
+13%
|
6 824
+10%
|
6 897
+1%
|
|
| Total Liabilities & Equity |
2 365
N/A
|
2 658
+12%
|
3 580
+35%
|
5 823
+63%
|
6 537
+12%
|
8 672
+33%
|
12 332
+42%
|
17 336
+41%
|
20 841
+20%
|
24 123
+16%
|
26 440
+10%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
374
|
674
|
674
|
749
|
749
|
777
|
788
|
1 136
|
1 136
|
1 137
|
1 132
|
|
Switch to:
Switch to:
See Also
Discover More
